BioBuzz Regional Roundup | Greater Philadelphia | March 24, 2025

Last week, BioBuzz hosted the second event in our BioInnovation series, centered on rare diseases. The event was a sell-out, with 160 attendees and an impressive 60%+ representation from biotech and pharma. We’re thrilled with the momentum and can’t wait for our upcoming AI x Bio event on April 9th!

Bryan Kennedy + Owen Buzy

BioBuzz Networks | Greater Philadelphia

philadelphia@biobuzz.io

• Philadelphia’s Proscia: Raises $50M to Advance AI-Driven Technology More

• Roche: settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds More

• Clario: announces acquisition of imaging provider NeuroRx More

• BioLabs: Expands and Rebrands Philadelphia Location as BioLabs for Advanced Therapeutics More

• Marengo Therapeutics: Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune Diseases More

• Paratek Pharmaceuticals: Will Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) More 

• Lungpacer Medical: will nearly double workforce to support first product launch More

• iECURE: Presentation of Full Data for the First Infant Dosed With ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting More

• BriaCell: Second Data Safety Monitoring Board Issues Positive Recommendation to Continue Phase 3 Study in Metastatic Breast Cancer More

• Incyte: Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa More

• ANI Pharmaceuticals: Launch of Nitazoxanide Tablets More

• Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema More

• Maxona Pharmaceuticals: MAX-001 Phase 1 Clinical Program Results More

• Virpax: Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND More

• CLEU Diagnostics: Former Alere and LumiraDx R&D Chief Nigel Lindner Joins to Launch Revolutionary LabSimple Diagnostic Platform More

• The Wistar Institute: Appoints welcomes Charles B. Cairns, M.D., Catherine Creese, and Carolyn Magill to the Board of Trustees More

Website | LinkedIn 

Ocugen, a fully integrated, patient-centric biotech company, is hiring for many roles including Head of Clinical Development and Vice President of Manufacturing & Supply.

• Harmony Biosciences (Plymouth Meeting, PA) - A leading pharma company dedicated to innovative therapies for patients with rare neurological diseases. Check out jobs here>

  • Director, Medical Writing

  • Senior Director, Clinical Pharmacology

  • Senior Director, Business Development

• Context Therapeutics (Philadelphia, PA) - A biopharma company advancing T cell engaging bispecific antibodies for solid tumors. Check out jobs here>

  • Head of Regulatory

  • Senior Director/VP, Data management

  • Director/Senior Director, Project Management

• Cabaletta Bio (Philadelphia, PA) - A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies here>

  • Director, Clinical Program Management

  • Director, Clinical Scientist

  • Senior Director, CMC Regulatory Affairs

• VintaBio (Philadelphia, PA) - Viral Vector Manufacturing. Check out jobs here>

  • Head of Analytical Development & Quality Control

  • Quality Assurance Document Control Training Manager

  • Office Manager

• Century Therapeutics (Philadelphia, PA) - Century Therapeutics is an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform. Check out jobs here>

  • Scientific Director, Upstream Process

  • Senior Director, Clinical Development

  • CMMS Specialist